Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

533
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
533
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

6.5K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.5K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.7K
Cancer Therapies02:49

Cancer Therapies

7.7K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.7K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.8K
Mouse Models of Cancer Study02:43

Mouse Models of Cancer Study

5.6K
Mice have long served as models for studying human biology and pathology because of their phylogenetic and physiological similarity with humans. They are also easy to maintain and breed in the laboratory, and hence, many inbred strains are now available for research. Studies on mice have contributed immeasurably to our understanding of cancer biology.
The development of transgenic, knockout, and knock-in mice has led to an exponential increase in their use as model organisms in research,...
5.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Targeting IL-17 family cytokines and receptors in hepatocellular carcinoma: From biology to combination immunotherapy.

Biochimica et biophysica acta. Reviews on cancer·2026
Same author

A systematic guide for identifying transcription factors that directly regulate the expression of a gene of interest.

Genome research·2026
Same author

Identification of a Novel Indolizine RORγT Inverse Agonist Using the AI-Driven Drug Design Platform.

ACS medicinal chemistry letters·2025
Same author

IL-17B Inhibits Hepatocellular Carcinoma Cell Proliferation.

Archivum immunologiae et therapiae experimentalis·2025
Same author

Staphylococcus aureus α-hemolysin induces DNA methylation changes in human Th1 cells.

Immunologic research·2025
Same author

The cyclin-dependent kinase inhibitor AT7519 is a human RORγt agonist.

Immunology and cell biology·2025

Related Experiment Video

Updated: Jul 11, 2025

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells
09:01

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Published on: March 7, 2025

390

RORγT agonists as immune modulators in anticancer therapy.

Joanna Pastwińska1, Iwona Karwaciak1, Kaja Karaś1

  • 1Laboratory of Epigenetics, Institute of Medical Biology, Polish Academy of Sciences, Lodowa 106, 93-232 Lodz, Poland.

Biochimica Et Biophysica Acta. Reviews on Cancer
|November 11, 2023
PubMed
Summary

RORγT agonists stimulate immune cells like Th17 lymphocytes, offering a new avenue for enhancing the immune response against cancer. This contrasts with inverse agonists, which are typically explored for autoimmune disease treatment.

Keywords:
Adoptive therapyAgonistsImmune system stimulationRORγTTc17Th17

More Related Videos

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation
15:04

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation

Published on: January 19, 2019

12.2K
Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
12:55

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

21.4K

Related Experiment Videos

Last Updated: Jul 11, 2025

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells
09:01

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Published on: March 7, 2025

390
Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation
15:04

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation

Published on: January 19, 2019

12.2K
Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
12:55

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

21.4K

Area of Science:

  • Immunology
  • Molecular Biology
  • Oncology

Background:

  • Retinoid-related Orphan Receptor gamma t (RORγT) is a transcription factor crucial for Th17 lymphocyte development and IL-17-expressing cells.
  • These RORγT-expressing cells play roles in host defense, autoimmune diseases, and cancer immunity.
  • RORγT activity is modulated by small-molecule ligands, with a focus on inverse agonists for autoimmune conditions.

Purpose of the Study:

  • To highlight the overlooked potential of RORγT agonists in therapeutic applications.
  • To review recent advancements in the biology of RORγT agonists.
  • To explore the application of RORγT agonists in anticancer therapy.

Main Methods:

  • Review of existing literature on RORγT biology and ligand development.
  • Analysis of studies investigating the role of RORγT-expressing cells in cancer immunity.
  • Synthesis of recent findings on RORγT agonists and their mechanisms.

Main Results:

  • RORγT agonists can stimulate Th17 and Tc17 lymphocytes, enhancing anti-tumor immune responses.
  • The development of RORγT agonists has been less explored compared to inverse agonists.
  • Recent research provides insights into the biological activities and therapeutic potential of RORγT agonists.

Conclusions:

  • RORγT agonists represent a promising therapeutic strategy for cancer treatment by boosting anti-tumor immunity.
  • Further research into RORγT agonists is warranted to fully exploit their potential in oncology.
  • This review emphasizes the dual role of RORγT modulation in autoimmune diseases and cancer.